Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma

Oncotarget

Volumn 6, Issue 11, 2015, Pages 9542-9550

  Jiang, Long ^a,b,c   Jiang, Shanshan ^a,b   Situ, Dongrong ^a,b   Lin, Yongbin ^a,b   Yang, Han ^a,b   Li, Yuanfang ^a,b   Long, Hao ^a,b   Zhou, Zhiwei ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunity; Metastasis; Prognosis; Soft tissue sarcoma

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD CELL RATIO; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROBLASTIC TUMOR; FIBROHISTIOCYTIC TUMOR; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOCYTE RATIO; MULTIVARIATE ANALYSIS; MUSCLE TUMOR; MYOFIBROBLASTIC TUMOR; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RISK FACTOR; SCHOOL CHILD; SEX; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION; TUMOR VOLUME; UNDIFFERENTIATED SARCOMA; UNIVARIATE ANALYSIS; BLOOD; BLOOD CELL COUNT; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MIDDLE AGED; MONOCYTE; MORTALITY; NEUTROPHIL; PROGNOSIS; RETROSPECTIVE STUDY; SARCOMA; SECONDARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA; YOUNG ADULT;

EID: 84928735989     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3283     Document Type: Article

References (55)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014; 64:9-29.
2. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008; 20:412-418.
3. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18:3108-3114.
4. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009; 10:126-140.
5. Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014; 3:1404-1415.
6. Briccoli A, Rocca M, Salone M, Bacci G, Ferrari S, Balladelli A, Mercuri M. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005; 104:1721-1725.
7. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T, Tomita K. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol. 2002; 20:3470-3477.
8. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005; 23:559-568.
9. Carter SR, Grimer RJ, Sneath RS, Matthews HR. Results of thoracotomy in osteogenic sarcoma with pulmonary metastases. Thorax. 1991; 46:727-731.
10. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009; 12:223-226.
11. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010; 6:149-163.
12. Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M. Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol. 1995; 34:69-73.
13. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91:181-184.
14. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in nonsmall cell lung cancer. J Thorac Cardiovasc Surg. 2009; 137:425-428.
15. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008; 34:55-60.
16. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32:1757-1762.
17. Shau HY, Kim A. Suppression of lymphokine-activated killer induction by neutrophils. J Immunol. 1988; 141:4395-4402.
18. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 2006; 139:755-764.
19. Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, Okunaga R, Shibata K, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg. 2007; 11:596-602.
20. Rosenberg AE. WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary. Curr Opin Oncol. 2013; 25:571-573.
21. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study, IV. J Clin Oncol. 2003; 21:78-84.
22. Rodeberg D, Arndt C, Breneman J, Lyden E, Donaldson S, Paidas C, Andrassy R, Meyer W, Wiener E. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV. J Pediatr Surg. 2005; 40:256-262.
23. Koscielniak E, Harms D, Henze G, Jurgens H, Gadner H, Herbst M, Klingebiel T, Schmidt BF, Morgan M, Knietig R, Treuner J. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999; 17:3706-3719.
24. Carli M, Colombatti R, Oberlin O, Bisogno G, Treuner J, Koscielniak E, Tridello G, Garaventa A, Pinkerton R, Stevens M. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma:final results and analysis of prognostic factors. J Clin Oncol. 2004; 22:4787-4794.
25. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, Et A. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13:610-630.
26. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
27. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. Bmc Cancer. 2001; 1:7.
28. Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. J Proteomics. 2009; 72:918-927.
29. Wong CP, Bray TM, Ho E. Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett. 2009; 276:38-46.
30. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Okumura H, Matsumoto M, Miyazono F, Hokita S, Aikou T. Tumorassociated macrophage (TAM) infiltration in gastric cancer. Anticancer Res. 2003; 23:4079-4083.
31. Lin JY, Li XY, Tadashi N, Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer. 2011; 30:280-286.
32. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002; 168:3536-3542.
33. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10:99-111.
34. Bruckner HW, Lavin PT, Plaxe SC, Storch JA, Livstone EM. Absolute granulocyte, lymphocyte, and moncyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach. JAMA. 1982; 247:1004-1006.
35. Elias EG, Leuchten JM, Buda BS, Brown SD. Prognostic value of initial mononucleated cell percentages in patients with epidermoid carcinoma of the head and neck. Am J Surg. 1986; 152:487-490.
36. Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, Wongkham S. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol. 2010; 161:471-479.
37. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol. 2001; 189:197-206.
38. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985; 134:230-234.
39. El-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987; 139:2406-2413.
40. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009; 58:15-23.
41. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology-Basel. 2007; 73:215-220.
42. Coley WB II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891; 14:199-220.
43. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma:an inter-institute NIH study. Med Pediatr Oncol. 2002; 38:158-164.
44. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29:917-924.
45. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy:moving beyond current vaccines. Nat Med. 2004; 10:909-915.
46. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002; 188:147-154.
47. Strbo N, Podack ER. Secreted heat shock protein gp96-Ig:an innovative vaccine approach. Am J Reprod Immunol. 2008; 59:407-416.
48. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol. 2005; 23:662-664.
49. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant PA. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol. 2012; 188:3080-3087.
50. Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S, Kawano K, Kawahara A, Kage M, Ohshima K, Yamanaka R, Shichijo S, Shirouzu K, Itoh K, Sasada T. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci. 2013; 104:1285-1294.
51. Ratnavelu K, Subramani B, Pullai CR, Krishnan K, Sugadan SD, Rao MS, Veerakumarasivam A, Deng X, Hiroshi T. Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report. Oncol Lett. 2013; 5:1457-1460.
52. Noguchi G, Ota J, Ishigaki H, Onuki T, Kato Y, Moriyama M. Nihon Hinyokika Gakkai Zasshi. 2012; 103:697-703.
53. Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old LJ, Ritter G. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma. 2013; 2013:168145.
54. Wilky BA, Goldberg JM. Immunotherapy in sarcoma: a new frontier. Discov Med. 2014; 17:201-206.
55. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer. Br J Surg. 2007; 94:1028-1032.